Roflumilast
Roflumilast

1.04
Manages airway inflammation and helps easier breathing patterns.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Roflumilast
Reference Brand
Daxas
Product Origin
Generic Product
Reference Manufacturer
AstraZeneca
Product Form
Tablet
Regulatory Classification
Rx
Primary Category
Respiratory Health
Product Category
Phosphodiesterase-4 Inhibitor
Pharmacological Class
Anti-inflammatory
Manufacturer Description
Utilized for chronic obstructive pulmonary disease to manage inflammation and support prevention of symptomatic flares.
Mechanism of Action
Roflumilast selectively inhibits the phosphodiesterase-4 (PDE4) enzyme. This action leads to increased intracellular cAMP in inflammatory cells, suppressing the release of cytokines that contribute to airway damage in COPD.
Route of Administration
Oral
Onset Time
4–8 weeks
Duration
24 hours
Contraindications
Moderate to severe hepatic impairment, Hypersensitivity to roflumilast
Severe Adverse Events
Suicidal ideation, Liver failure, Anaphylaxis — requires immediate medical attention
Common Side Effects
Diarrhea, Weight loss, Nausea
Uncommon Side Effects
Insomnia, Headache, Decreased appetite
Drug Interactions
Alcohol, Rifampin, Erythromycin, Ketoconazole, Phenobarbital
Pregnancy Safety Warnings
FDA Category C: Use only if potential benefit outweighs risk. Breastfeeding: Not recommended.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Storage Guidelines
Store at room temperature.
Related Products
Daxas, Daliresp
Information related to Roflumilast is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
Where to buy Contraceptives UK - Yasmin Price Ireland